Safety and tolerance of rapidly infused Depacon® - A randomized trial in subjects with epilepsy

Epilepsy Research

Volumn 52, Issue 3, 2003, Pages 189-201

  Ramsay, R E ^a   Cantrell, D ^b   Collins, S D ^c   Walch, J K ^c   Naritoku, D K ^d   Cloyd, J C ^e   Sommerville, K ^c  

^a UNIVERSITY OF MIAMI   (United States)

^b North Texas Neuroscience Center   (United States)

^c ABBOTT LABORATORIES   (United States)

^d SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Epilepsy; Intravenous infusion; Safety; Seizures; Valproate

Indexed keywords

VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHENIA; BRAIN DISEASE; CHILD; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG LABELING; DRUG SAFETY; DRUG TOLERANCE; DYSPEPSIA; DYSPNEA; EPILEPSY; FEMALE; HUMAN; HYPOTENSION; INJECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STUPOR; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VERTIGO; VOMITING;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANTICONVULSANTS; BLOOD PRESSURE; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; VALPROIC ACID;

EID: 0037231979     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(02)00187-0     Document Type: Article

References (34)

1. Abbott Laboratories, 2000. Depacon® [valproate sodium injection package insert]. North Chicago, IL.
2. Alfonso I., Perea A., Paez J.C., Dunoyer C., Yelin K., Alvarez L. Intravenous valproic acid dose in neonates [abstract]. Epilepsia. 40:(Suppl. 7):1999;143.
3. Alvarez L., Dunoyer C., Gilman J., Alfonso I., Resnick T., Duchowny M., Jayakar P. Safety and dose/level relationship in rapid intravenous loading of valproic acid in children under age 12 years [abstract]. Epilepsia. 40:(Suppl. 7):1999;143.
4. Beydoun A., Sackellares J.C., Shu V. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Neurology. 48:1997;182-188.
5. Bourgeois B.F.D. Valproic acid-clinical use. Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs. 4th ed. 1995;Raven Press, New York.
6. Cavanaugh J.H., Hussein Z., Lamm J., Granneman G.R. Pharmacokinetics of multiple oral dose divalproex sodium after intravenous loading dose administration in healthy volunteers. Drug Invest. 7:1994;1-7.
7. Czapinski P., Terczynski A. Intravenous valproic acid administration in status epilepticus [in Polish]. Neurol. Neurochir. 32:1998;11-22.
8. Edwards K.R., Shea P., Behnke M. Acute treatment of migraine headache with intravenous valproate (Depacon) [abstract]. Epilepsia. 40:(Suppl. 7):1999;143.
9. Granneman G.R., Lamm J.E., Cavanaugh J.H. Assessment of pharmacokinetics of sodium valproate injectable [abstract]. Epilepsia. 30:1989;668.
10. Honack D., Loscher W. Intravenous valproate: onset and duration of anticonvulsant activity against a series of electroconvulsions in comparison with diazepam and phenytoin. Epilepsy Res. 13:1992;215-221.
11. Hussein Z., Mukherjee D., Lamm J., Cavanaugh J.H., Granneman G.R. Pharmacokinetics of valproate after multiple-dose oral and intravenous infusion administration: gastrointestinal-related diurnal variation. J. Clin. Pharmacol. 34:1994;754-759.
12. Hussein Z., Patterson K.J., Lamm J.E., Cavanaugh J.H., Granneman G.R. Effect of infusion duration on valproate pharmacokinetics. Biopharm. Drug Dispos. 14:1993;389-399.
13. Kriel R.L., Birnbaum A.K., Norberg S.K., Wical B.S., Le D.N., Cloyd J.C. Pharmacokinetics of total and unbound valproate after rapid infusion of Depacon [abstract]. Epilepsia. 40:(Suppl. 7):1999;232.
14. Leniger T., Hufnagel A. Nonconvulsive status epilepticus treated with intravenous valproate [abstract]. Epilepsia. 40:(Suppl. 7):1999;149.
15. Levy R.H., Shen D.D. Valproate Absorption, Distribution, and Excretion. Antiepileptic Drugs. 3rd ed. 1989;Raven Press, Ltd, New York.
16. Limdi N.A., Faught E. Safety of rapid infusion of intravenous valproic acid [abstract]. Epilepsia. 40:(Suppl. 7):1999;144.
17. Mattson R.H., Cramer J.A., Collins J.F. A comparison of valproate with carbamazepine for the treatment of complex partial and secondarily generalized tonic-clonic seizures. N. Engl. J. Med. 313:1985;145-151.
18. Naritoku D.K., Mueed S. Intravenous loading of valproate for epilepsy. Clin. Neuropharmacol. 22:1999;102-106.
19. Parke-Davis, 1999. Cerebyx [fosphenytoin sodium injection package insert]. Morris Plains, New Jersey.
20. Perucca E., Gatti G., Frigo G.M., Crema A. Pharmacokinetics of valproic acid after oral and intravenous administration. Br. J. Clin. Pharmacol. 5:1978;313-318.
21. Peters C.N.A., Pohlmann B. Preliminary experiences with intravenous valproate with special regard to status epilepticus [abstract]. Neurology. 52:(Suppl. 2):1999;A249.
22. Peters C.N.A., Pohlmann-Eden B. Efficacy and safety of intravenous valproate in status epilepticus [abstract]. Epilepsia. 40:(Suppl. 7):1999;149-150.
23. Ramsay R.E., Cantrell D.E., Johnson M.E., DeToledo J., Rogue H., Lowe M.R., Pryor F.M. Safety of high-dose rapid infusion of intravenous valproic acid [abstract]. Neurology. 54:2000;A11.
24. Sachdeo R.C., Leroy R.F., Krauss G.L., Drake M.E., Green P.M., Leppik I.E., Shu V.S., Ringham G.L., Sommerville K.W. Tiagabine therapy for complex partial seizures. A dose-frequency study. Arch. Neurol. 54:1997;595-601.
25. Sherman S.J. A retrospective review of the use of intravenous valproic acid in a university-based tertiary-care hospital including use for status epilepticus [abstract]. Epilepsia. 40:(Suppl. 7):1999;95.
26. Short D.W., Pack A.M., Brazil C.W. Depacon administration, safety, and efficacy in a hospital setting [abstract]. Epilepsia. 40:(Suppl. 7):1999;226.
27. Sinha S., Naritoku D. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology. 55:2000;422-424.
28. Treiman D.M., Meyers P.D., Walton N.Y., Collins J.F., Colling C., Rowan J., Handforth A., Faught E., Calabrese V.P., Uthman B.M., Ramsay E., Mamdani M.B. A comparison of four treatments for generalized convulsive status epilepticus. N. Engl. J. Med. 339:1998;792-798.
29. Turski W.A., Cavalheiro E.A., Coimbra C., da Penha Berzaghi M., Ikonomidou-Turski C., Turski L. Only certain antiepileptic drugs prevent seizures induced by pilocarpine. Brain Res. 434:1987;281-305.
30. Uthman B.M., Rowan A.J., Ahmann P.A., Leppik I.E., Schacter S.C., Sommerville K.W., Shu V. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch. Neurol. 55:1998;56-62.
31. Venkataraman V., Wheless J.W. Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res. 35:1999;147-153.
32. Walton N.Y., Treiman D.M. Valproic acid treatment of experimental status epilepticus. Epilepsy Res. 12:1992;199-205.
33. Wheless J., Venkataraman V. Safety of high intravenous valproate doses in epilepsy patients. J. Epilepsy. 11:1998;319-324.
34. Willmore L.J., Shu V., Wallin B. Efficacy and safety of add-on divalproex sodium in the treatment of complex partial seizures. Neurology. 46:1996;49-53.